Abstract
Qatar, a state that has a diverse population consisting mainly of foreign residents, has experienced a large COVID19 outbreak. In this study, we report on 2634 SARS-CoV-2 whole-genome sequences from infected patients in Qatar between March-2020 and March-2021, representing 1.5% of all positive cases in this period. Despite the restrictions on international travel, the viruses sampled from the populace of Qatar mirrored nearly the entire global population’s genomic diversity with nine predominant viral lineages that were sustained by local transmission chains and the emergence of mutations that are likely to have originated in Qatar. We reported an increased number of mutations and deletions in B.1.1.7 and B.1.351 lineages in a short period. These findings raise the imperative need to continue the ongoing genomic surveillance that has been an integral part of the national response to monitor the SARS-CoV-2 profile and re-emergence in Qatar.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This project was supported by finds from the Qatar Genome project (QGP), Qatar Petroleum (project number: QUEX-BRC-QP-PW-18/19 and QUEX-BRC-QP-GH-18/19), and Qatar University. Statements made herein are solely the responsibility of the authors.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Institutional Review Board (IRB) committees of Qatar University (QU-IRB 1289-EA/20) and Hamad Medical Corporation (MRC-01-20-145) ethical boards. Samples collected were retrospective as such, in accordance with the national legislation and the institutional requirements, written informed consent for participants was not required for this study.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All generated SARS-CoV-2 genome in this study were deposited to the Global Initiative on Sharing All Influenza Data (GISAID). Accession IDs are listed in Supplementary Data 2.
